ClinicalTrials.gg

Program

Verteporfin

Also written as “Verteporfin Photodynamic Therapy”, “Verteporfin Injection” and “Photodynamic Therapy (PDT) with Visudyne (verteporfin)”.

Its studies are mostly in Macular Degeneration · Prostatic Neoplasms · Breast Neoplasms · Polypoidal Choroidal Vasculopathy, led by 4 companies.

Furthest: phase 4, since Aug 24, 20058 company-led studies, 2 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis40 open or runningphase 4since Aug 24, 2005Aug 24, 2005none ahead
SpectraCure AB22 open or runningphase 2since Feb 13, 2017Feb 13, 2017Jul 31, 2027phase 2 · NCT03067051
QLT10 open or runningphase 3since Jul 12, 2005Jul 12, 2005none ahead
Rogers Sciences10 open or runningphase 2since Oct 18, 2016Oct 18, 2016none ahead

Also a collaborator on its studies: Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 12, 2005First study: phase 3 study in Macular DegenerationNew to QLTQLT · NCT00121407 · 364 enrolled
  2. Aug 24, 2005Novartis's first study: phase 4 study in Macular DegenerationNew to NovartisNovartis · NCT00135837 · 202 enrolled · Switzerland
  3. Feb 8, 20072 phase 3 studies in Macular DegenerationNovartis · NCT00433017, NCT00436553
  4. May 5, 2008Phase 4 study in Polypoidal Choroidal VasculopathyNovartis · NCT00674323 · 61 enrolled · Hong Kong, Korea, Republic of, Singapore and more
  5. Oct 18, 2016Rogers Sciences's first study: phase 2 study in Breast NeoplasmsNew to Rogers SciencesRogers Sciences · NCT02939274 · 15 enrolled · United States
  6. Feb 13, 2017SpectraCure AB's first study: phase 2 study in Prostatic NeoplasmsNew to SpectraCure ABSpectraCure AB · NCT03067051 · 66 planned · United States, Canada, Sweden and more
  7. Jan 29, 2025Phase 2 study in Prostatic NeoplasmsSpectraCure AB · NCT06807359 · 43 planned · United States, Germany

Ahead

  1. Jul 31, 2027Primary completion: phase 2 study in Prostatic NeoplasmsSpectraCure AB · NCT03067051
  2. Jan 2028Primary completion: phase 2 study in Prostatic NeoplasmsSpectraCure AB · NCT06807359

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06807359Prostatic Neoplasms · United States, Germany2RecruitingSpectraCure ABJan 202843
NCT03067051Prostatic Neoplasms · United States, Canada, Sweden and more2RecruitingSpectraCure ABJul 31, 202766
NCT02939274Breast Neoplasms · United States2UNKNOWNRogers SciencesDec 201815
NCT00674323Polypoidal Choroidal Vasculopathy · Hong Kong, Korea, Republic of, Singapore and more4CompletedNovartisMay 200961
NCT00436553Macular Degeneration · United States, Canada3CompletedNovartisOct 2009321
NCT00433017Macular Degeneration · Austria, Belgium, Denmark and more3TerminatedNovartisJul 2009255
NCT00135837Macular Degeneration · Switzerland4CompletedNovartis202
NCT00121407Macular Degeneration3CompletedQLT364

How it is read

Names in the registry

  • “Verteporfin Photodynamic Therapy”, 3 entries
  • “Verteporfin”, 2 entries
  • “Verteporfin Injection”, 1 entry
  • “Photodynamic Therapy (PDT) with Visudyne (verteporfin)”, 1 entry
  • “Verteporfin for injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.